Posted by Michael Wonder on 20 Apr 2021
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer
20 April 2021 - NICE has today published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.
Today’s decision means it will be the first time trastuzumab deruxtecan (also called Enhertu and jointly developed and commercialised by Daiichi-Sankyo and AstraZeneca) has been commissioned for use in any European country.
